AstraZeneca received approval from the Japanese regulator following a priority review of Tagrisso (osimertinib) as a first-line treatment of patients with positive non-small cell lung cancer ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

The FibroGen-AstraZeneca drug, marketed as Evrenzo, is currently approved in China, Europe, Japan, and over 40 other countries for the treatment of anemia in patients with chronic kidney disease.

AstraZeneca's Imfinzi (durvalumab) plus chemotherapy, has gained CHMP recommendation for approval in the EU to treat NSCLC.

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

Regulatory reviews for the treatment regimen are currently underway in the EU, Japan and other countries. "AstraZeneca’s Imfinzi bladder cancer regimen improves survival in Phase III trial" was ...

AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for ...

In 2024, there were roughly 43,000 drug-treated patients in the US, European Union, and Japan with early-stage and locally advanced gastric or GEJ cancer. Approximately 62,000 patients in these ...